JP2023520591A - Ｓａｒｓ－ｃｏｖ－２感染症の治療のための２５－ヒドロキシビタミンｄ - Google Patents

Ｓａｒｓ－ｃｏｖ－２感染症の治療のための２５－ヒドロキシビタミンｄ Download PDF

Info

Publication number
JP2023520591A
JP2023520591A JP2022560917A JP2022560917A JP2023520591A JP 2023520591 A JP2023520591 A JP 2023520591A JP 2022560917 A JP2022560917 A JP 2022560917A JP 2022560917 A JP2022560917 A JP 2022560917A JP 2023520591 A JP2023520591 A JP 2023520591A
Authority
JP
Japan
Prior art keywords
hydroxyvitamin
day
subject
days
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022560917A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520591A5 (enExample
Inventor
チャールズ ダブリュー ビショップ
スティーヴン エイ ストラグネル
アクタル アシュファク
リーム エラメイン エルシディグ
コルム ナルティ
Original Assignee
エアジェン ファーマ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エアジェン ファーマ リミテッド filed Critical エアジェン ファーマ リミテッド
Publication of JP2023520591A publication Critical patent/JP2023520591A/ja
Publication of JP2023520591A5 publication Critical patent/JP2023520591A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2022560917A 2020-04-06 2021-04-06 Ｓａｒｓ－ｃｏｖ－２感染症の治療のための２５－ヒドロキシビタミンｄ Pending JP2023520591A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202063006034P 2020-04-06 2020-04-06
US63/006,034 2020-04-06
US202063006563P 2020-04-07 2020-04-07
US63/006,563 2020-04-07
US202063009155P 2020-04-13 2020-04-13
US63/009,155 2020-04-13
US202063012781P 2020-04-20 2020-04-20
US63/012,781 2020-04-20
US202063032714P 2020-05-31 2020-05-31
US63/032,714 2020-05-31
PCT/IB2021/000220 WO2021205225A1 (en) 2020-04-06 2021-04-06 25-hydroxyvitamin d for the treatment of sars-cov-2 infection

Publications (2)

Publication Number Publication Date
JP2023520591A true JP2023520591A (ja) 2023-05-17
JP2023520591A5 JP2023520591A5 (enExample) 2024-04-18

Family

ID=75904967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022560917A Pending JP2023520591A (ja) 2020-04-06 2021-04-06 Ｓａｒｓ－ｃｏｖ－２感染症の治療のための２５－ヒドロキシビタミンｄ

Country Status (8)

Country Link
US (2) US20210308151A1 (enExample)
EP (1) EP4132477A1 (enExample)
JP (1) JP2023520591A (enExample)
KR (1) KR20220164539A (enExample)
CN (1) CN116033940A (enExample)
CA (1) CA3176559A1 (enExample)
TW (1) TW202203936A (enExample)
WO (1) WO2021205225A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526980A (ja) * 2020-05-31 2023-06-26 エアジェン ファーマ リミテッド ハードカプセル剤形及びその使用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2862462B2 (es) * 2020-04-06 2023-04-27 Servicio Andaluz De Salud Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
CN116785295A (zh) * 2023-06-29 2023-09-22 吉林大学 雷特格韦在防治新型冠状病毒感染药物中的应用
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525985A (ja) * 2006-02-03 2009-07-16 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー ２５−ヒドロキシビタミンｄ２及び２５−ヒドロキシビタミンｄ３によるビタミンｄ不足及び欠乏の治療
JP2010525078A (ja) * 2007-04-25 2010-07-22 シトクロマ インコーポレイテッド ビタミンｄ化合物およびワックス状担体を含有する制御放出性経口組成物
JP2019510045A (ja) * 2016-03-28 2019-04-11 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
FR2757173A1 (fr) 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
KR100379674B1 (ko) 2000-03-06 2003-04-10 주식회사 서흥캅셀 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법
US20080031957A1 (en) 2006-05-15 2008-02-07 Deluca Hector F Pulmonary delivery of 1alpha,25-dihydroxyvitamin D3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
JP2017523220A (ja) * 2014-08-07 2017-08-17 オプコ アイルランド グローバル ホールディングス リミテッド ２５−ヒドロキシビタミンｄを用いる補助的療法
JP7603000B2 (ja) 2018-08-31 2024-12-19 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ小児用剤形、製造方法および使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009525985A (ja) * 2006-02-03 2009-07-16 プロヴェンティヴ セラピュティックス リミテッド ライアビリティ カンパニー ２５−ヒドロキシビタミンｄ２及び２５−ヒドロキシビタミンｄ３によるビタミンｄ不足及び欠乏の治療
JP2010525078A (ja) * 2007-04-25 2010-07-22 シトクロマ インコーポレイテッド ビタミンｄ化合物およびワックス状担体を含有する制御放出性経口組成物
JP2019510045A (ja) * 2016-03-28 2019-04-11 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JSBMB, vol. 203, JPN6025053150, August 2020 (2020-08-01), pages 1 - 6, ISSN: 0005763263 *
NUTRIENTS, vol. 12, JPN6025012508, 2 April 2020 (2020-04-02), ISSN: 0005561554 *
日本感染症学会症例報告, JPN6025053151, May 2020 (2020-05-01), ISSN: 0005763262 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526980A (ja) * 2020-05-31 2023-06-26 エアジェン ファーマ リミテッド ハードカプセル剤形及びその使用

Also Published As

Publication number Publication date
CA3176559A1 (en) 2021-10-14
CN116033940A (zh) 2023-04-28
KR20220164539A (ko) 2022-12-13
EP4132477A1 (en) 2023-02-15
WO2021205225A1 (en) 2021-10-14
US20210308151A1 (en) 2021-10-07
WO2021205225A8 (en) 2023-01-05
US20250144119A1 (en) 2025-05-08
TW202203936A (zh) 2022-02-01

Similar Documents

Publication Publication Date Title
US20250144119A1 (en) Activating endogenous antimicrobials to treat sars-cov-2 infection
JP7526143B2 (ja) 好酸球性食道炎を処置する方法
CN100349573C (zh) 用于亲脂性药物的制剂
JP6463714B2 (ja) 二次性副甲状腺機能亢進症の治療及び予防方法
US8080528B2 (en) Compositions and methods for treatment of cachexia
US20230255942A1 (en) Crf1 receptor antagonist for the treatment of congenital adrenal hyperplasia
KR102158948B1 (ko) 약물 전달 시스템
US20240100029A1 (en) Treatment of migraine
CN107405309A (zh) 用于治疗肥胖症和相关代谢紊乱的奥利司他和阿卡波糖的调释组合物
US20230181463A1 (en) Oleogel and oleopaste compositions and uses thereof
US20140329782A1 (en) Combined therapeutic agent
US20230330110A1 (en) Hard capsule dosage form and uses thereof
CN115397431A (zh) 用于治疗涉及全身过度炎症反应的病症的eclitasertib
WO2021195119A1 (en) Methods of reducing the risk of, severity of, and treating coronavirus infections
TW200408409A (en) Oral administration of calcitonin
EP4225440A1 (en) Methods for delivering medium chain triglycerides with controlled pharmacokinetic, safety and tolerability profiles
TWI728959B (zh) 不穩定或難溶藥物的口服投予
Yakar et al. The effect of tocilizumab on severe COVID-19 infection: Review of current evidence.
WO2021132302A1 (ja) 透析移行又は腎死の抑制のための薬剤
ES2862462B2 (es) Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
US20250262163A1 (en) Combination and Uses and Treatments Thereof
US20240009154A1 (en) Methods and compositions for treating cytokine release syndrome
EA041800B1 (ru) Способ лечения коронавирусной инфекции
JP2023156545A (ja) コロナウイルスによる感染症治療用の医薬組成物
EP4326279A1 (en) Universal dosage regime of 25-hydroxy vitamin d3

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260406